Protalix BioTherapeutics, Inc. filed an 8-K on November 3, 2026, announcing it will release financial results for the quarter ended September 30, 2026, and host a conference call at 8:00 a.m. Eastern Time on November 10, 2026.

Key Highlights

  • Results date: Financial results for the quarter ended September 30, 2026, will be released on November 10, 2026.
  • Conference call: Management will host a call at 8:00 a.m. Eastern Time on Tuesday, November 10, 2026.
  • Conference ID: 13763420, with a replay available for two weeks following the event.
  • Listing: The company trades on NYSE American under the ticker PLX (NYSE American:PLX).
  • Business focus: Protalix describes itself as a biopharmaceutical company focused on rare diseases, with two enzyme replacement therapies currently available in multiple markets.
  • Regulatory milestone: According to the filing, Protalix is "the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system."

Protalix Schedules Q3 2026 Earnings Call and Business Update

According to the filing, Protalix BioTherapeutics (NYSE American:PLX) will release its third-quarter 2026 financial results and provide a business update on November 10, 2026. Management is scheduled to discuss those results alongside "recent corporate and regulatory developments" during the live call, which begins at 8:00 a.m. Eastern Time. Participants are requested to access the call at least 15 minutes ahead of the scheduled start time to register and install any necessary audio software.

The company disclosed that a replay of the call will be available for two weeks on the Events Calendar of the Investors section of its website. Protalix operates as a biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases. The filing states that Protalix manufactures two enzyme replacement therapies produced via its proprietary plant cell-based expression system, ProCellEx, which the company describes as enabling recombinant protein production "in an industrial-scale manner with no exposure to mammalian cells."

The filing further notes that Protalix has licensed worldwide development and commercialization rights to taliglucerase alfa (Elelyso) to Pfizer Inc. for the treatment of Gaucher disease, excluding Brazil, where Protalix retains full rights. The company has also partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio, which received approval from both the FDA and the European Medicines Agency in May 2023. The development pipeline, according to the filing, includes PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases.

What Was Disclosed

Protalix BioTherapeutics announced via an 8-K filed November 3, 2026, that it will release Q3 2026 financial results and host a management conference call on November 10, 2026, at 8:00 a.m. Eastern Time, with a webcast replay available for two weeks afterward.